Sanaria Inc.
Clinical trials sponsored by Sanaria Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New malaria vaccine trial aims to block infection without causing illness Results expected Sep 2026 (estimated)
- New malaria vaccine shows promise in african trial Results expected Feb 2027 (estimated)
-
Could a Liver-Stage malaria vaccine shield mothers and babies?
Vaccine Recruiting nowThis phase 2 trial tests a new malaria vaccine (PfSPZ-LARC2) designed to stop the malaria parasite in the liver before it can cause illness. The study involves 300 healthy women of childbearing age in Mali who plan to become pregnant. Participants receive three doses of the vacci…
Phase 2 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Jul 25, 2026 00:00 UTC
-
New malaria vaccine trial aims to block infection without causing illness
Vaccine Recruiting nowThis early-stage trial tests a new malaria vaccine (PfSPZ-LARC2) in 58 healthy adults who have never had malaria. The vaccine uses weakened malaria parasites that stop growing in the liver and cannot cause blood infection. Researchers will check if it is safe and if it protects a…
Phase 1 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Jun 27, 2026 14:01 UTC
-
New malaria vaccine shows promise in african trial
Vaccine Recruiting nowThis study tests a new malaria vaccine in 180 healthy adults aged 18-50 in Burkina Faso. The vaccine uses weakened malaria parasites that stop growing in the liver, so they cannot cause blood-stage infection. Participants receive either one or two doses of the vaccine or a placeb…
Phase 2 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Jun 27, 2026 13:01 UTC